ORLANDO, FL USA (UroToday.com) - Stage T4 RCC is defined as extension of tumor beyond Gerota’s fascia and/or invading into the adrenal gland. Patients with higher stage and advanced disease tend to have poor outcomes. Dae Y. Kim stated that patient counseling and surgical intervention is essential for patients with higher-risk disease. Therefore, their objective in this study was to determine variables that can predict survival in patients with T4 RCC.

auaThe authors identified 67 patients with T4 disease. Both clinical and pathological variables were assessed in each patient, and they analyzed survival using Kaplan-Meier method.

They found that median survival was 18 months longer for patients who had lymph node dissection. After analysis, they found that predictors of survival were M stage at time of surgery, lymph node status and dissection, and histology of the tumor including sarcomatoid features in the tumor.

The authors concluded that median survival increases tremendously with lymph node dissection. Furthermore, they found that there are multiple variables that can potentially predict outcomes of patients with T4 disease. These findings are significant, and the authors concluded that having knowledge of predictors for each particular patient may assist in the informed decision-making process with regards to disease management. Surgeon preference may be related to the decision of lymph node dissection. Thus, this may introduce a bias with patient selection.

Presented by Dae Y. Kim at the American Urological Association (AUA) Annual Meeting- May 16 - 21, 2014 - Orlando, Florida USA

Houston, TX USA

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com


Upcoming urology industry events
April 27-29, 2018 / European Society for Medical Oncology Update for Practising Oncologists
European Society for Medical Oncology Update for Practising Oncologists
May 14, 2018 / InterContinental Mark Hopkins Hotel
SITC Cancer Immune Responsiveness Workshop
May 16-17, 2018 / InterContinental Mark Hopkins Hotel
SITC Immuno-Oncology Biomarkers: State of the Art Workshop
May 17, 2018 / Moscone Convention Center North/South, San Francisco, CA
SAU 2018 Annual Meeting at the AUA
Print publications focusing on urological cancer treatments through original commentary & articles

Everyday Urology™ - Oncology Insights

From the Editor

Prostate Cancer and Prostatic Diseases

From the Editor